Trurapi (insulin aspart)

pCPA File Number: 22347
Negotiation Status:
Concluded with an LOI
Indication(s):
Diabetes mellitus in patients who require insulin for the control of hyperglycemia (normally to be used in regimens together with an intermediate or long-acting insulin), or continuous subcutaneous insulin infusion (CSII) in pump systems which are licensed in Canada for Trurapi insulin infusion
Sponsor/Manufacturer:
Sanofi-Aventis Canada Inc.
CDA-AMC Project Number:
Not Applicable
pCPA Engagement Letter Issued:
Negotiation Process Concluded: